Navigation Links
Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
Date:11/10/2011

LEXINGTON, Mass., Nov. 10, 2011 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company completed its first close of $2.2 million of a Series A angel-led financing. Cherrystone Angels of Providence, Rhode Island led the round, with participation from Boston Harbor Angels and other undisclosed individuals. Mr. Robert Manning, the co-Chairman of Cherrystone Angels, will join the Avaxia board. Mr. Manning has served as a senior executive at Citigroup and on a number of early-stage company boards, including SmartCells.

Dr. Barbara Fox, Avaxia's founder and CEO, commented, "This investment will allow us to aggressively pursue the development of our AVX-470 anti-TNF oral antibody and prepare Avaxia to initiate a clinical trial in inflammatory bowel disease next fall. When coupled with the funding we have received from BARDA (Biomedical Advanced Research and Development Authority) to develop AVX-470 for GI Acute Radiation Syndrome, our investors have a unique opportunity to participate in the rapid creation of value in two important disease areas. We are in advanced discussions with a limited number of other qualified investors as we work to complete this planned round of financing. The angel community's response to Avaxia has been very gratifying."

The funds from this financing will be used to manufacture drug to be used in the clinical trial and to conduct final pre-clinical studies in advance of a Phase 1b clinical trial in patients with inflammatory bowel disease, being planned for the second half of 2012. The company has raised $4.3 million in non-dilutive financing prior to this equity round. In addition to a loan from the Massachusetts Life Sciences Center and several SBIR grants, the company was awarded a $2.9 million, 2-year contract with BARDA that fully funds the initial research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.

About Cherrystone Angel Group:  The Cherrystone Angel Investor Group, based in Providence, Rhode Island, offers early stage investment funds to companies in Rhode Island, Connecticut and Massachusetts.

About Avaxia Biologics, Inc.:  Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
2. Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
3. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
4. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
5. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
6. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
7. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
8. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
9. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
10. Creabilis Raises €15M ($20M) in Series B Fundraising Round
11. SironRX Therapeutics Raises $3.4 Million Series A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 23, 2017 , ... Federal funding for basic and applied scientific research — ... and other vital technologies — deserves continued support, say leaders of SPIE, the ... today in responding to the President’s budget request for Fiscal Year 2018. , The ...
(Date:5/24/2017)... 2017 As Ebola resurfaces in the ... 20 suspected cases now reported, a new analysis of the ... a correlation between the 2014 and 2017 outbreaks of the ... in 2012-13, which preceded the 2014 outbreak. An analysis of ... Replikin counts in 2014-15, which again precedes the current outbreak ...
(Date:5/23/2017)... Westminster, Colorado (PRWEB) , ... May 23, 2017 , ... ... amaranth as the most troublesome and difficult to control weed in 12 categories of ... found. , Almost 200 weed scientists across the U.S. and Canada participated in the ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... this month its 20th anniversary, marking the occasion with a strong presence at ... meeting’s Welcome Reception and further extends an invitation to all attendees to view ...
Breaking Biology Technology:
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):